Evidence profile
CJC 1295 NO DAC (10 mg Vial)
The long-acting CJC-1295 studies commonly cited online cannot automatically support a product labeled NO DAC.
01
Product identity
The absence of DAC changes which study material is an appropriate match.
DAC and non-DAC CJC-1295 are distinct active moieties; evidence for the long-acting DAC form does not establish equivalence.[3]
02
What has been studied
Primary human study
Why the commonly cited study needs context
- Population or model
- Healthy adults aged 21–61
- Study route or material
- Subcutaneous, study protocol
The 2006 human study evaluated a long-acting GHRH analogue and prolonged hormone responses. It should not be treated as direct validation of NO DAC material.[1]
03
Evidence limits
A matching human evidence assessment for the exact NO DAC product is not complete.
A name similarity does not establish an equivalent half-life, dosing schedule or outcome.
The reviewed sources do not establish patient instructions for this product. No dose, cycle, preparation method or administration schedule is provided here.
04
Formulation and handling evidence
Exact amino-acid sequence, terminal modifications and explicit DAC status.
Manufacturer documents linking those identity details to the current product.
A compatible diluent, prepared-solution stability and container/device compatibility must be supported for the exact formulation. The diluent manufacturer’s instructions do not supply a universal storage period for every dissolved substance.[4]
05
Approval context
This profile has not established Canadian authorization of the linked research product.[2]
06
Sources and review scope
- Long-acting CJC-1295 study in healthy adultsPrimary human study · Fresh primary abstract and indexed identity · Checked 2026-09-09
- Health Canada: unauthorized injectable peptide productsRegulatory advisory · Fresh Health Canada advisory read, including product/DIN and RUO-label limits · Checked 2026-09-09
- FDA CJC-1295 identity review: DAC and non-DAC active moietiesRegulatory scientific review; 2024 briefing · Fresh PDF pages 6–9, identity/interchangeability passages · Checked 2026-09-09
- Hospira/Pfizer: bacteriostatic water manufacturer informationManufacturer information; US presentation · Fresh manufacturer page, relevant compatibility/storage/supply passages · Checked 2026-09-09
- Amino Labs: CJC-1295 NO DAC | 10mgSupplier listing; identity reference · Exact heading, SKU, form and supplier URL from the full catalogue capture; not stock-lot authentication · Checked 2026-09-09
This is a selected-source evidence summary. It is not a systematic review, formal certainty grade or qualified clinical sign-off. Study dates and source-check dates are distinct.